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gene superfamily (IgSF) and has an important role in a
number of endothelial cell functions including angiogen-
esis, inflammation, integrin activation and cell-cell
adhesion. CD31 has both homotypic and heterotypic
adhesive properties and in common with other IgSF
members contains multiple functional domains. Using
chimaeric fusion proteins of CD31 and a panel of
haematopoietic cell lines we show that CD31 can bind cells
in a predominantly homotypic or heterotypic manner
depending on the cell line used. Heterotypic binding was
found to be cation and temperature dependent and
enhanced by Mn2+: all features of integrin mediated
binding. Using a panel of anti-CD31 and anti-integrin anti-
bodies we show that a vb 3 is a ligand for CD31 on the
monocytic cell line U937. The specificity of the interaction
between a vb 3 and CD31 was further confirmed by solid
phase binding assays and the use of a vb 3 transfected cells
which bound CD31 specifically. Furthermore, we have
mapped the binding site for a vb 3 to domains 1 and 2 of
CD31. The interaction of CD31 with a vb 3 may be important
in many aspects of endothelial function including leukocyte-
endothelial transmigration and angiogenesis. 
Key words: Cell adhesion molecule, Integrin, Endothelium,
Monocyte
SUMMARYINTRODUCTION
CD31 (PECAM-1) is a cell adhesion molecule (CAM) the
extracellular domain of which consists of six Ig C2-related
domains (Simmons et al., 1990; Newman et al., 1990;
Stockinger et al., 1990). It is highly expressed on endothelium,
platelets, about 50% of lymphocytes and cells of myeloid
lineage (De Lisser et al., 1994b). It is also expressed on CD34+
haematopoietic progenitor cells in human bone marrow (Watt
et al., 1993, 1995a,b). In both endothelial and monocytic cells
the turnover of CD31 at the cell surface is rapid; the t1/2 being
approximately 24 hours (Goldberger et al., 1994). 
CD31 has been implicated in a number of biological events,
primarily involving inter-endothelial adhesion (Muller et al.,
1989; Schimmenti et al., 1992) and leukocyte-endothelial
adhesion and transmigration (Muller et al., 1993). A number
of animal model studies, using CD31 antibodies, have shown
that CD31 is involved in monocyte and neutrophil recruitment
during inflammation (Vaporciyan et al., 1993; Bogen et al.,
1994). However, CD31 expression on leukocytes is not a pre-
requisite for transendothelial migration (Bird et al., 1993). 
CD31 is also involved in adhesion amplification via b 1 and
b 2 integrins (Tanaka et al., 1992; Piali et al., 1993; Berman and
Muller, 1995). The molecular basis of this cross talk between
CD31 and integrins is undefined. However, it is not restricted
to haematopoietic cells as it can also occur in heterologousprimate cells (Fawcett et al., 1995). Moreover, co-ligation of
CD31 with FcRg II in monocytes leads to the production of pro-
adhesive cytokines (Chen et al., 1994). CD31 has also been
implicated in T cell and platelet activation with both de novo
phosphorylation on serine and threonine residues and cell
surface redistribution of CD31 being observed as cells are
activated (Newman et al., 1992; Zehnder et al., 1992; Romer
et al., 1995). Together these results suggest that CD31 may act
as a signalling molecule.
CD31 mediated adhesion is complex involving both
homotypic and heterotypic interactions. Homotypic binding
involves extensive interdigitation of CD31 on apposing cells
and requires all six domains. Key binding sites reside in
domains 2-3 and 5-6 (Fawcett et al., 1995). A heterotypic
binding site is located within domain 2 which contains a
consensus sequence for glycosaminoglycan (GAG) binding
(Muller et al., 1992; DeLisser et al., 1993). However, domain
6 also appears to be involved in heterotypic binding as the
epitopes for two monoclonal antibodies that block heterotypic
but not homotypic binding map to this domain (DeLisser et al.,
1994; Yan et al., 1995). CD31 therefore appears to contain
multiple functional domains capable of mediating quite
different ligand-receptor interactions. How these adhesive
options are regulated is not fully understood but a direct role
for the cytoplasmic tail has been demonstrated (Baldwin et al.,
1994; DeLisser et al., 1994a).
438 C. D. Buckley and othersThe CD31 gene has a relatively complex structure encom-
passing more than 65 kb of DNA organized into 16 exons
(Kirschbaum et al., 1994). At least three alternatively spliced
forms have been identified, one of which encodes a soluble
form lacking the transmembrane domain (Goldberger et al.,
1994) and in the mouse several splice variants of the cyto-
plasmic tail have been defined. In view of the recent report that
soluble forms of E-selectin and VCAM-1 can act as potent
angiogenic stimuli (Koch et al., 1995), soluble and secreted
variants of CD31may have a role in angiogenesis.
Studies on the role of CD31 have mainly concentrated on its
function on endothelium and leukocytes. However, the role of
CD31 in haematopoietic development is poorly understood.
Haematopoietic progenitor cells as well as macrophages in the
stroma of long term bone marrow cultures both express CD31
(Watt et al., 1993, 1995a,b). Moreover, ligation of CD31 on
CD34+ haematopoietic cells seems to result in the activation
of VLA-4 but not LFA-1 providing further evidence for the
role of CD31 as an adhesion amplifier (Leavesley et al., 1994).
In order to explore the repertoire of binding modes of CD31
on haematopoietic cells we screened a panel of cell lines rep-
resenting various stages of myeloid and lymphoid lineage
development for adhesion to recombinant chimeric forms of
human CD31. We found that some cell lines (KG1B, MIK
ALL) bound to CD31 in a predominantly homotypic manner
whereas others (U937) bound in a predominantly heterotypic
manner. Recently, another laboratory examining the adhesion
of murine lymphokine-activated killer (LAK) cells and pro-T-
cells to recombinant forms of truncated murine CD31 reported
that the integrin a vb 3 is an additional receptor for CD31 (Piali
et al., 1995). In agreement with these findings, we confirm that
in the human, CD31 can mediate heterotypic adhesion to a vb 3.
Furthermore, by using a series of truncated soluble recombi-
nant forms of CD31 in combination with blocking monoclonal
antibodies we map the integrin heterotypic binding site to
domains 1 and 2 of CD31.
MATERIALS AND METHODS
Cells and reagents
All the cell lines used in this study except MIK-ALL were provided
by the Imperial Cancer Research Fund (ICRF) Cell Production
Service and were maintained in RPMI/10% FCS. MIK-ALL was
cultured as previously described (Watt et al., 1993). The production
of K562 cells stably transfected with a v b 3 (Kavb3) or vector alone
(KRc/RSV) has been described (Blystone et al., 1995). These cells
were maintained in either RPMI or IMDM/10%FCS containing 1.2
mg/ml G418 (Genticin, Gibco). All reagents used were from Sigma
Chemical Co., unless otherwise specified.
Antibodies
The following monoclonal antibodies (mAbs) were used. Anti-CD31
mAbs were: 9G11 (Simmons et al., 1990); L133.1 (Becton Dickinson,
Oxford, UK); hec 7.2 (Endogen, TCS Biologicals Ltd, Bucks, UK);
5.6E (Immunotech, Marseille, France); 10B8 (British Bio-technology,
Oxford, UK); CLB/CD31 (Monosan, Bucks, UK); HC1/6 (Serotec,
Kidlington, UK); JC70A (provided by Dr J.Cordell, John Radcliffe
Hospital, Oxford, UK); CAL31.1 IgG1 (which maps to domain 6 of
CD31) was generated in mice after immunisation with a CD31(D1-
D6)-Fc chimeric fusion protein. Anti-integrin antibodies were: anti-
a 2 integrin clone HAS-6 (ICRF Biotherapeutics and Hybridoma
Development Unit, South Mimms, UK); anti-a 3 integrin clone P1B5(Becton Dickinson, Oxford, UK); anti-a 4 integrin clone HP2/1
(Immunotech, Marseille, France); anti-a 5 integrin clone IIA1
(PharMingen, Cambridge Bioscience, Cambridge, UK); anti-a 6
integrin clone GoH3 (Serotec, Kidlington, UK) anti-a v integrin clone
L230 (provided by Dr J. Marshall, Richard Dimbleby Department of
Cancer Research, ICRF Laboratory, Guy’s and St Thomas’s Hospital,
London UK); anti-b 1 integrin clone 13 (Becton Dickinson, Oxford,
UK); anti-b 2 integrin MHM23 (Dako, Bucks, UK); anti-b 3 integrin
clone RUU-PL 7F12 (Becton Dickinson, Oxford, UK); anti-a v b 3
integrin clone LM609 (Chemicon International, Harrow, UK) and
clone 23C6 (ICRF Biotherapeutics and Hybridoma Development
Unit, South Mimms, UK). Control antibody was anti-VCAM clone
BBIG-V1 (R&D systems, Abingdon, Oxford). Polyclonal goat anti-
human-Fc Ig was obtained from Sigma Chemical Co. 
Chimeric fusion proteins
The CD31 chimeric fusion proteins used in this study consisted of the
appropriate NH2 terminal IgC2 domains of CD31 fused to the Fc
region of human IgG1, and have been previously described
(Simmons, 1993; Fawcett et al., 1995). A negative control chimeric
IgSF-Fc fusion protein (MUC18-Fc) was generated as described pre-
viously (Fawcett et al., 1992). All Fc chimeric proteins were purified
from COS-1 cell supernatants as previously described (Simmons,
1993), and checked by SDS-PAGE.
Cell adhesion assays
Cell adhesion to soluble chimeric fusion proteins was carried out as
previously described (Fawcett et al., 1995) with the following modi-
fications. 96-well adhesion assay plates (Immulon-3; Dynatech
Research Laboratories, Chantilly, Virginia, USA) were precoated
with 1 m g/well goat anti-human IgGFc and nonspecific sites blocked
with 0.4% BSA (Fraction V). Recombinant Fc proteins in PBS were
added at 0.5 m g/well. This concentration of Fc protein was shown to
be saturating by both ELISA and adhesion assays. Cells were labelled
by incubation with the fluorescent dye BCECF-AM (Molecular
Probes, Oregon, USA) for 30 minutes and washed twice in assay
buffer (RPMI-20 mM Hepes, 0.2% BSA). The labelled cells were
added at 1· 105 cells/well and incubated for 30-35 minutes at 37°C.
Plates were washed with prewarmed assay buffer until the cells in the
control wells were sufficiently removed as monitored by visual
inspection. Typically this was 2-3 times. The attached cells were
quantitated using a fluorescence plate reader Cytofluor II (Millipore,
Watford, UK) and the percentage of input cells bound calculated after
measuring the total fluorescence prior to washing. For some assays,
cells were labelled for 24-48 hours with [3H]thymidine (Amersham,
Bucks, UK) adherent cells lysed in 1% SDS and incorporated radioac-
tivity counted using a Beckman LS 5000 CE counter.
In experiments where mAbs were added, cells were preincubated
with antibodies at a final concentration of 10 m g/ml for 10 minutes at
room temperature prior to plating and included throughout the assay.
In experiments to analyse the effects of Mn2+ on cell binding, MnCl2
was diluted in assay buffer at a final concentration of 0.5 mM and
added to the plated cells in each well. 
All adhesion assays were performed on at least two independent
occasions. Each data point represents the mean of three replicates and
the data are expressed as the % of input cells bound ± 1 s.d.
Purification of a vb 3 and solid-phase binding assay
a v b 3 was purified from the human melanoma cell line DX3. Cells
were lifted with 2 mM EDTA in PBS, washed in PBS and lysed in
50 ml of 150 mM NaCl, 2 mM CaCl2, 0.02% NaN3, 1% NP40, 20
mM Tris-HCl, pH 7.5, 1 mM PMSF, 5 m g/ml leupeptin, 5 m g/ml
aprotinin, on ice for 1 hour. The cell lysates were centrifuged at
26,000 rpm and then passed over a 23C6 affinity column (prepared
by coupling 23C6 to CNBr-activated Sepharose (Pharmacia)
according to the manufacturer’s instructions). The column was
washed in 150 mM NaCl, 2 mM CaCl2, 0.02% NaN3, 0.1% NP40,
439a vb 3 is a ligand for CD3120 mM Tris-HCl, pH 7.5, and bound material eluted with 150 mM
NaCl 1% octyl-glucopyranoside, 10 mM sodium acetate, pH 3.1, and
0.5 ml fractions collected and neutralised with 0.1 ml 1 M Tris-HCl,
pH 8.0. Pooled fractions were concentrated using a centricon con-
centrator (Amicon), and aliquots stored at - 70°C. The integrin prepa-
ration was pure as judged SDS-PAGE (Fig. 6A) and ELISA using
anti- a v b 3 mAbs. 
Solid-phase binding was performed using a modification of the
method of Charo et al. (1990). Purified a v b 3 (0.2 mg/ml) was diluted
1:50 in TBS 0.02% NaN3 containing 1 mM CaCl2 (Buffer A) and 100
m l aliquots added to a 96-well Nunc-Maxisorp ELISA plate (Gibco,
Life Technologies). Plates were incubated overnight at 4°C and
blocked with 200 m l 5% BSA in buffer A for 1-3 hours at room tem-
perature. Wells were then washed 3 times in TBS, 1 mM CaCl2, 1
mM MnCl2, 1 mg/ml BSA (Buffer B). Aliquots (100 m l) of the Fc
protein ligands (at 5 m g/ml) were added with or without mAbs and
the plate incubated at 30°C for 3 hours. Wells were washed 3 times
in buffer B and bound Fc ligand detected by the addition of peroxi-
dase-conjugated anti-huuman Fc antibody (1:2,000) in buffer B for 30
minutes at room temperature. Wells were then washed 4 times in
buffer B and colour developed using OPD substrate (Sigma). The
level of non specific binding was determind by the level of ligand
binding to wells coated with BSA alone; these values were subtracted
from all samples.
Immunofluorescence
Cells were incubated in PBS 0.2% BSA, 5 mM azide at 4°C for 20
minutes with the appropriate antibody at 10 m g/ml followed by FITC
labelled goat anti-mouse Ig (or in some cases anti-rat Ig). The median
fluorescence intensity was measured on a FACScan (Becton
Dickinson, Oxford, UK) and at least 2,000 cells per sample were
analysed.
Synthetic peptides
Synthetic peptides LKREKN, NKERKL and REKNLK, used in this
study, were synthesised on a Zinsser SMPS 350 multiple peptide syn-
thesiser using standard Fmoc solid phase chemistry and were
purchased from Zinsser Analytic, Maidenhead, Berks, UK. These
peptides have been used in a previous study (DeLisser et al., 1993)
and correspond to residues 150-155 of CD31 (LKREKN), the reverse
sequence (NKERKL) and a peptide with the same residue in a
scrambled order (REKNLK). Both the 150-155 peptide and its
reverse sequence have been shown to block glycosaminoglycan
(GAG) mediated heterotypic binding (DeLisser et al., 1993). The
peptides were purified by high performance liquid chromatography
(HPLC) prior to use and sequence confirmed by mass spectrometry.
All three peptides were water soluble and stored in PBS at - 20°C
prior to use.0
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CD31RESULTS
Cell-chimeric protein adhesion screen for CD31
binding modes
In order to further explore the binding modes of CD31, we
screened a panel of 11 haematopoietic cell lines representing
different lineages and stages of development: KG1, KG1A and
KG1B (myeloblastic progenitors); Raji, Namalwa and Daudi
(B cell), MIKALL (pre-B cell); Molt 4 and HSB2 (T cell);
U937 (pro-monocyte), and K562 (erythroleukaemic), for their
ability to bind to soluble recombinant CD31(D1-D6)Fc
chimeric protein immobilized on plastic via anti-Fc polyclonal
antibodies (Fig. 1). The Fc fusion proteins were used at 0.5
m g/well. This system eliminates the possibility of accessory
cell-cell interactions which may contribute to background
binding in a two-cell system, and is quantitative and repro-
ducible. Moreover, it allows for normalisation of the amount
of chimeric protein presented to input cells. We have previ-
ously used this approach to define and dissect the homotypic
binding mode of CD31 (Fawcett et al., 1995). Of the 11 cell
lines screened, three (KG1B, MIK-ALL and U937) bound con-
stitutively and specifically to CD31(D1-D6)Fc and not to a
control IgSF-Fc fusion protein MUC-18Fc. (Fig. 1). All three
of these cell lines express CD31 on their surface. However,
there was no correlation between the level of CD31 expressed
by these cells and their ability to bind to CD31(D1-D6)Fc. The
binding of the pro-monocytic cell line U937 to CD31(D1-
D6)Fc was much stronger than any homotypic adhesion pre-
viously measured on haematopoietic cells e.g. MIK-ALL
(Fawcett et al., 1995) and suggested that additional mecha-
nisms of CD31 adhesion were operating in this cell line. This
was confirmed by the following analysis.
Pattern of cell binding to CD31(D1-D6)Fc deletion
series
To further define the nature of CD31 mediated adhesion to
U937, KG1B and MIK-ALL, we examined the ability of a
nested series of chimeric truncation mutants of CD31-Fc to
support binding of these three cell lines. This series of
truncated forms of CD31 consists of NH2 terminal 1, 1-2, 1-3,
1-4, 1-5 and 1-6 IgC2 domains of CD31 fused to the Fc region
of human IgG1 which are designated CD31(D1)Fc, CD31(D1-
D2)Fc, CD31(D1-D3)Fc, CD31(D1-D4)Fc, CD31(D1-D5)Fc
and CD31(D1-D6)Fc. Fig. 2B,C, shows that for both KG1BU
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Fig. 1. Cell-chimeric protein adhesion screen of
haematopoietic cell lines. Adhesion of 11
haematopoietic cell lines (KG1, KG1A, KG1B,
Raji, Namalwa, Daudi, MIK-ALL, MOLT-4,
HSB2, U937 and K562) to CD31(D1-D6)Fc or a
control IgSF-Fc fusion protein. MUC-18Fc is
included as a negative control for each cell line and
represents the background level of adhesion in the
assay. Results are expressed as the percentage of
total input cells bound ± 1 s.d. (n=3).
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Fig. 2. Pattern of cell binding to CD31Fc chimeric deletion series.
Adhesion of (a) U937, (b) KG1B, (c) MIK-ALL to CD31 deletion
chimeras. The series used was CD31(D1)Fc, CD31(D1-D2)Fc,
CD31(D1-D3)Fc, CD31(D1-D4)Fc, CD31(D1-D5)Fc and CD31(D1-
D6)Fc. Background adhesion is to a control protein, MUC18-Fc.
Results are expressed as percentage of total input cells bound ± 1 s.d.
(n=3).
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Fig. 3. Lack of involvement of GAGs in adhesion of U937 to
CD31(D1-D6)Fc. (a) Effect of heparin. U937 binding to CD31(D1-
D6)Fc is not inhibitable by heparin. Cells were allowed to bind in the
presence or absence of 100 m g/ml heparin. Background binding is
represented by binding to MUC18-Fc. (b) Effect of peptide
mimetics. U937 binding to CD31(D1-D6)Fc is not inhibited in the
presence of peptide mimetics of the putative GAG recognition
sequence in CD31. Cells were incubated in the absence or presence
of three concentrations (100 m g/ml, 500 m g/ml and 1,000 m g/ml) of
the peptide LKREKN which exactly mimics the sequence of CD31
(residues 150-155); the reverse sequence peptide NKERKL, and a
scrambled sequence peptide REKNLK. Background binding is
represented by binding to MUC18-Fc. Results are expressed as
percentage of total input cells bound ± 1 s.d. (n=3). and MIK-ALL the presence of domain 6 of CD31 was
necessary to support significant binding. However, for U937,
all the truncation mutants, including the minimal unit
CD31(D1)Fc, were able to support significant binding,
although for maximal binding the minimal unit was CD31(D1-
3)Fc. Domains 4, 5 and 6 did not contribute further to the
binding of U937 (Fig. 2A). This suggested that U937 interacted
with CD31 in a completely different manner to KG1B and
MIK-ALL, and not at all like the previously established
homotypic mode. Since homotypic binding has been shown torequire the correct alignment of all six domains of CD31
(Fawcett et al., 1995), this suggested that U937 was binding
CD31 in a predominantly heterotypic rather than homotypic
manner, and that a novel CD31 counter receptor was expressed
by U937.
Heterotypic U937-CD31(D1-D6)Fc interaction does
not occur via glycosaminoglycans
A CD31 heterotypic adhesion mode has been reported that
involves a site within the second Ig domain of CD31 binding
to as yet undefined cell associated glycosaminoglycans
(GAGs) (Muller et al., 1992; DeLisser et al., 1993). This
binding can be completely blocked by heparin at 100 m g/ml.
In addition, short linear peptide sequence recognition motifs
have been identified within domain 2 of CD31 (position 150-
155 LKREKN, and the reverse NKERKL) that are believed to
441a vb 3 is a ligand for CD31engage the GAG structures (DeLisser et al., 1993). We
performed adhesion assays in the presence of these reagents.
However, none of these reagents blocked the binding of U937
to CD31(D1-D6)Fc (Fig. 3A and B). These data, together with
the fact that CD31(D1)Fc, could support significant binding
suggested that a novel, non-GAG dependent counter-receptor
existed on U937. 
Cation, temperature dependence and Mn2+
regulation of CD31 mediated adhesion to U937
To further investigate the nature of this new counter-receptor,
we examinined whether binding to CD31 was dependent on
cations and temperature. As shown in Fig. 4A,B the binding of
U937 to CD31(D1-D6)Fc was sensitive to both divalent
cations and temperature. The lack of complete inhibition by
EDTA and EGTA suggests that a small component of CD31
homotypic, cation independent binding was occurring when
U937 bound CD31(D1-D6)Fc. This cation and temperature
dependence suggested that the heterotypic counter-receptor on
U937 might be an integrin. This was further enforced by theFig. 4. Cation and temperature dependence of U937 adhesion to
CD31(D1-D6)Fc. (a) Cation dependence. Adhesion of U937 cells to
plastic coated with CD31(D1-D6)Fc. Cells were incubated in assay
buffer alone (0.42 mM Ca2+, 0.4 mM Mg2+) or washed three times in
HBSS containing 2 mM EDTA and then assayed in HBSS in the
presence of 2 mM EDTA or 2 mM EGTA. (b) Temperature
dependence. Adhesion of U937 cells to CD31(D1-D6)Fc either
incubated at 37°C or 4°C. For both a and b, the background level of
binding is indicated by adhesion to MUC18-Fc. Results are
expressed as percentage of total input cells bound ± 1 s.d. n=6 for a;
n=3 for b. 
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bfact that the addition of 0.5 mM Mn2+ doubled the binding of
U937 to CD31(D1-D6)-Fc. However, the same concentration
of Mn2+ did not increase the binding of KG1B or MIK-ALL
(data not shown). Mn2+ regulation is a characteristic feature of
integrin mediated binding (Karecla et al., 1995). This stongly
suggested that the novel counter-receptor on U937 cells was
an integrin.
Adhesion of U937 to CD31(D1-D6)Fc is inhibited by
antibodies to a vb 3
To identify the integrin that binds CD31, we established the
surface integrin profiles of the three cell lines, U937, KG1B
and MIK-ALL, known to bind CD31(D1-D6)Fc. U937 binds
CD31 predominantly by the novel integrin heterotypic counter-
receptor, compared with KG1B and MIK-ALL, which bind
CD31 solely by the homotypic mode. The aim of establishing
surface integrin profiles was to determine if there were any
integrins that were unique to and/or expressed on U937, that
were not on KG1B and MIK-ALL. By using a panel of anti-
integrin a and b chain antibodies and flow cytometry we found
that the integrin a vb 3 was expressed on U937, but not on
KG1B or MIK-ALL (Table 1). 
We then screened a further panel of anti-integrin adhesion
blocking antibodies for their ability to inhibit the binding of
U937 to CD31(D1-D6)Fc. Only antibodies to a v (L230) and
a vb 3 (LM609) were able to completely inhibit binding to back-
ground levels (Fig. 5). In contrast, a non-blocking antibody to
a vb 3 (mAb 23C6) did not affect binding suggesting that
blockade by LM609 was not due to non specific steric effects.
Blocking mAbs to other integrins expressed on U937 (a 3, a 5,
and b 2) did not affect binding. Although some inhibition did
occur with antibodies to a 4, b 1 and b 3 this inhibition was
within the limits of plate to plate variation of control cell
binding. These results demonstrated that a vb 3 was the integrin
ligand mediating U937 binding to CD31(D1-D6)Fc.
Specificity of the a vb 3 CD31 interaction
To provide additional evidence for a specific interaction
between a vb 3 and CD31 we examined the binding of
CD31(D1-D6)Fc to purified a vb 3 using a solid phase assay
(Fig. 6A,B). This showed that the interaction between CD31
and a vb 3 was specific as a control protein MUC-18Fc did not
bind a vb 3. Antibodies to both CD31 and a vb 3 inhibitedTable 1. Expression of integrin subunits by cell lines
Median fluorescence intensity
Antibody Integrin U937 KG1B MIK-ALL
IgG1 Control 5.8 7.7 5.2
HAS-6 a 2 33.9 8.0 n/t
P1B5 a 3 16.5 4.8 6.0
HP2/1 a 4 67.3 45.3 69.7
IIA1 a 5 54.3 31.6 77.7
GoH3 a 6 12.8 10.7 40.6
13 b 1 107.5 69.8 119.7
MHM23 b 2 58.3 74.9 11.9
LM609 a vb 3 22.9 8.6 5.8
9G11 CD31 67.3 56.3 46.9
Fluorocytometry was used to determine integrin expression on the three
cells lines as described in the materials and methods. Results are expressed as
the median fluorescence intensity. Background fluorescence was determined
by incubation with a mouse IgG1 control mAb (BBIG-V1). n/t, not tested.
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Fig. 5. Antibodies to a v b 3 block adhesion of U937 to CD31(D1-
D6)Fc. Adhesion of U937 to CD31(D1-6)Fc in the absence or
presence of a panel of blocking mAbs to integrins expressed on the
surface of U937. Cells were incubated with mAbs at 10 m g/ml for 10
minutes at room temperature before the assay and then the cells were
plated in 96-well plates coated with CD31(D1-D6)Fc as described in
Materials and Methods. mAbs were present throughout the assay.
The mAbs were: anti-a 3 integrin P1B5, anti-a 4 integrin HP2/1, anti-
a 5 integrin IIA1, anti-a v integrin L230, anti-a v b 3 integrin LM609,
anti-a v b 3 integrin 23C6, anti-b 1 integrin 13, anti-b 2 integrin
MHM23, anti-b 3 integrin RUU-PL 7F12. Background binding is
represented by binding to MUC18-Fc. Two ‘no antibody’ values
from the two separate plates used in this experiment are shown to
indicate plate to plate variation of control binding. Results are
expressed as percentage of total input cells bound ± 1 s.d. (n=3). 
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Fig. 6. CD31(D1-
D6)Fc binds to
purified immobilised
a v b 3. (a)
Characterization of
purified a v b 3. SDS-
PAGE analysis of
immunopurified a vb 3
under reduced and
non reduced
conditions. Lane 1,
reduced; lane 2,
empty; lane 3, non
reduced; lane 4,
protein markers.
Molecular mass
markers are indicated
(in kDa). The proteins
were separared on a
7.5% gel and stained
with Coomassie Blue.
The a v and b 3 chains
run at 150 and 90 kDa
(non reduced), and
125 and 105 kDa
(reduced). (b) Binding
of CD31 (D1-D6)Fc
to immoblilzed a v b 3.
CD31(D1-D6)Fc or
the control protein
MUC-18Fc were
added to wells coated
with a vb 3 in the
presence or absence of
EDTA (2 mM), the
a v b 3 mAb LM609 (10
m g/ml) or the CD31
mAb L133.1 (10 m g/ml) and incubated for 3 hours at 30°C. A
peroxidase-conjugated anti-human Fc antibody was used to detect
bound Fc proteins, and background binding of this antibody to BSA
subtracted from all samples. Results are expressed as the mean
(OD450 nm) ± 1 s.d. (n=6).
a
bbinding as did 2 mM EDTA confirming the specificity of the
CD31/a vb 3 interaction. 
As further evidence for the specificity of the CD31/a vb 3
interaction we examined the binding of K562 cells (which do
not express endogenous a vb 3) transfected with a vb 3 to
CD31(D1-D6) Fc. Fig. 7 shows that only cells transfected with
a vb 3 bound CD31(D1-D6)Fc. Mock transfected cells did not
bind CD31(D1-D6)Fc. Furthermore neither transfected nor
mock transfected cells bound MUC-18Fc. These K562 trans-
fected cells express a vb 3 but no CD31 and therefore can only
engage in heterotypic binding. 
Mapping the a vb 3 binding site on CD31 by adhesion
blockade
From the pattern of U937 binding to the CD31-Fc deletion
series it was apparent that the binding site for a vb 3 on CD31
resided at least in part in domain 1 (Fig. 2A).
To determine whether any other domains of CD31 had addi-
tional contribution to CD31-a vb 3 mediated adhesion, a panel
of 9 anti-CD31 mAbs were screened for their ability to block
CD31-a vb 3 binding (Fig. 8). This also allowed us to directly
compare the blocking abilities of mAbs known to inhibit
homotypic binding (Fawcett et al., 1995) with their ability to
inhibit a vb 3-CD31 adhesion. The anti-CD31 domain 2 mAbs5.6E and L133.1 inhibited binding to background levels. Both
these mAbs have been shown to inhibit CD31 homotypic
binding. (Fawcett et al., 1995). The anti-CD31 mAb hec 7.2
which maps to the D1-D2 boundary (Muller et al., 1993),
partially inhibited binding. None of the other anti-CD31 mAbs
9G11, JC70A, CLB/CD31, HC1/6, 10B8 and CAL31.1
affected binding. These results suggest that domain 2 of CD31
may contribute to the binding site for a vb 3.
DISCUSSION
It has already been established that CD31 exhibits both
homotypic and heterotypic adhesive properties. The homotypic
mode involves anti-parallel inter-digitation of apposing CD31
molecules. However, the identity of the heterotypic counter-
receptor(s) has not been defined, but may involve gly-
cosaminoglycans. By using an adhesion assay that relies on the
presentation of a nested series of truncated forms of CD31
made as Fc fusion proteins we have been able to define an alter-
native CD31 binding mode on the pro-monocytic cell line
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Fig. 7. K562 cells transfected with a v b 3 bind CD31(D1-D6)Fc.
Adhesion of K562 cells stably transfected with a vb 3 or vector alone
to wells coated with either CD31(D1-D6)Fc or MUC-18Fc. Cells
were washed three times in TBS and incubated in TBS with 0.5 mM
Mn2+ for 30 minutes at 37°C. Background binding is represented by
binding to MUC-18Fc. Results are expressed as percentage of total
input cells bound ± 1 s.d. (n=6). U937. This stategy has allowed us to extend our previous
studies on the mapping of the homotypic binding sites in CD31
(Fawcett et al., 1995) to demonstrate that the CD31+ U937 cell
line binds to CD31(D1-D6)Fc in a very different manner to
other CD31+ leukocytic cell lines. Significant, though not
maximal, adhesion occurred with the CD31(D1)Fc fusionFig. 8. Antibodies to D1-D2 of CD31 block binding of U937 to
CD31(D1-D6)Fc. Adhesion of U937 to CD31(D1-D6)Fc in the
absence or presence of a panel of mAbs to various domains of CD31.
Assays were performed as in Fig. 5. The mAbs were: anti-CD31(D1)
9G11 and JC70A; anti-CD31(D2) 5.6E, L133.1 and CLB/CD31;
anti-CD31(D1-D2) hec 7.2; anti-CD31(D4-D5) HC1/6; anti-
CD31(D5) 10B8 and anti-CD31(D6) CAL31.1. Background binding
is represented by binding to MUC18-Fc. Results are expressed as
percentage of total input cells bound ± 1 s.d. (n=3). 
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cprotein. This pattern of binding was unlike that observed for
homotypic binding where the lack of any one of the six
domains of CD31 leads to loss of binding (Fawcett et al., 1995)
and suggested that a novel heterotypic counter-receptor for
CD31 existed on U937 cells. 
Using a combination of biochemical and mAb blocking
assays we found that the heterotypic ligand on U937 did not
involve cell surface GAGs but instead was the integrin a vb 3.
Direct evidence for the specificity of the CD31/a vb 3 interac-
tion was obtained through a combination of solid phase binding
assays and the binding of a vb 3 transfectants to CD31. These
results confirm for human CD31 a similar observation made
by Piali et al. (1995) for murine CD31
.
From the work of Piali et al. (1995), and our present study,
the concomitant expression of a vb 3 and CD31 by a cell may
modulate any potential CD31 homotypic binding, with het-
erotypic binding dominating over homotypic binding.
We have shown that CD31 can bind cells in a predominantly
homotypic or heterotypic manner depending on the cell line
used. We found that U937 bound CD31 in a predominantly
heterotypic manner but that homotypic adhesion could also
occur at a low level, since U937 binding to CD31 was not com-
pletely inhibited by EDTA or EGTA (Fig. 4A). This suggests
that both homotypic and heterotypic modes of binding can
operate in parallel. The preferential usage of one adhesion
pathway over another to regulate overall cell adhesion has been
demonstrated for other integrin/IgSF interactions. For
example, there appears to be a hierarchy of binding pathways
for the integrins LFA-1 and VLA-4 which are co-expressed on
leukocytes (Van Kooyk et al., 1993). Moreover, recent obser-
vations in both humans and the mouse have shown that E-
cadherin can mediate both homotypic (between epithelial cells)
and also heterotypic interactions through adhesion to the
mucosal T cell integrin a E b 7 (Cepek et al., 1994; Karecla et
al., 1995).
The a vb 3 integrin is expressed on U937 but not on KG1B or
MIK-ALL both of which bind CD31 solely in a homotypic
manner. U937 cells, however, bind CD31 in a predominantly
heterotypic manner. Furthermore, because U937 cells bind to
CD31(D1-D6)Fc constitutively, this suggests that a vb 3 on
U937 is expressed in an already activated state which can be
further activated by Mn2+ ions, a well established external
activator of integrin adhesion. The molecular mechanisms that
regulate the adhesive phenotype (homotypic versus heterotypic)
of CD31 expressing cells remain unknown. Some clues about
possible regulatory mechanisms come from the work of
DeLisser et al. (1994a) who showed that deletions of the cyto-
plasmic tail of CD31 can switch CD31 mediated adhesion from
predominantly heterotypic (GAG-mediated, not via a vb 3) to
predominantly homotypic binding. Only the extracellular
portions of CD31 are necessary for homotypic binding to occur
as measured by direct protein-protein interactions using surface
plasmon resonance (our unpublished observations).
The binding site for a vb 3 on CD31 resides at least in part in
domain 1. Utilising the CD31-Fc chimeric deletion series, we
established that CD31(D1)Fc alone could support nearly
maximal binding. In addition, three anti-CD31 blocking mAbs
(2 of which by ELISA map to domain 2, and one to the domain
1/domain 2 boundary) block the a vb 3-CD31 interaction. This
implies that domain 2 contributes to the binding site. These
mAbs may however exert their blocking activity by sterically
444 C. D. Buckley and othershindering the access of a vb 3 to domain 1 of CD31. Maximal
binding of a vb 3 to CD31 occurs with CD31(D1-D3)Fc. This
could implicate a contribution from domain 3 but also could
be due to optimal accessiblity and presentation of CD31 to
a vb 3 away form the anti-Fc coated plastic surface used for the
adhesion assays. Domains 4, 5 and 6 do not yield any increase
in binding. The issue of accessibility of the IgSF chimeric
protein to its counter-receptor also seems to be true of the inter-
action of ICAM-1 with its receptor on Plasmodium falciparum
infected erythrocytes (Berendt et al., 1992). The ICAM-1-
binding site for malaria infected erythrocytes maps to the first
2 domains yet adhesion to a shortened version of ICAM-1 con-
taining these domains is reduced presumably due to steric
hindrance. Therefore from our data we conclude that the
binding site for a vb 3 on CD31 resides predominantly in domain
1 but that domain 2 may contribue to the binding site. 
Both the domain 2 mAbs which are known to block
homotypic binding (Fawcett et al., 1995) also blocked het-
erotypic binding to a v b 3. Significantly the hec 7.2 mAb which
is known to inhibit monocyte transendothelial migration but
does not inhibit homotypic or GAG-mediated heterotypic
adhesion, partially inhibited a vb 3 mediated heterotypic
adhesion. This mAb has been mapped to the D1-D2 boundary
(Muller et al., 1993; Yan et al., 1995). Since D2 has been
shown to be important on GAG mediated heterotypic binding
(De Lisser et al., 1993), these results suggest that D1 and D2
play central roles in mediating homotypic and heterotypic
adhesion, and that the binding sites for homotypic and a vb 3
mediated heterotypic adhesion must partially overlap, at least
as measured by mAb epitope mapping.
From studies which have attempted to map the binding sites
of those IgSF members which bind integrins (LFA-1-ICAM 1,
2, 3; VLA-4-VCAM, a 4b 7-Mad-CAM), a model has emerged
which emphasises the dominance of domains 1 and 2 (Holness
and Simmons, 1994). Moreover, mutagenesis studies coupled
with the crystal structure of vascular cell adhesion molecule-1
(Jones et al., 1995) have suggested that a common structural
motif for integrin binding to IgSF members is the presence of
an aspartate or glutamate residue in the C-D loop of the Ig like
domain to which binding occurs (Bergelson and Hemler, 1995;
Loftus et al., 1994). Sequence alignments of CD31 domains 1
and 2 against VCAM-1 domain 1, show that both D1 and D2
of CD31 have aspartate or glutamate residues at exposed
regions in their C-D loops (data not shown and Watt et al.,
1995a). These residues are key targets for mutagenesis to
further define the a vb 3 binding site.
There is much direct evidence implicating CD31 in the
transendothelial migration of monocytes (Muller et al., 1993).
Our results, and those for murine CD31 (Piali et al., 1995),
suggest that CD31 dependent monocyte interaction with
endothelium occurs via a vb 3, since the hec 7.2 mAb, which is
known to inhibit transmigration, partially blocks a vb 3-
mediated heterotypic adhesion to CD31(D1-D6)1Fc. Interest-
ingly, the anti-b 3 mAb RUU-PL 7F12, which is known to block
some b 3 mediated cell matrix functions, did not fully block
binding to CD31(D1-D6)Fc, suggesting that the binding site
for CD31 on a vb 3 may be distinct from that for matrix
molecules. There are many such examples of selective
blocking of ligand binding by mAbs to integrins (Ruiz et al.,
1993; Landis et al., 1994; Neugebauer and Reichardt, 1991).
The fact that the ligand repertoire of a vb 3 includes both CD31and ECM molecules such as vitronectin, fibronectin and
laminin suggests that as transmigration occurs a vb 3 may
become increasingly activated and able to switch from cell-cell
to cell-ECM engagement. In fact it appears to be a general
trend for integrins to display a broader range of ligand speci-
ficity as they become more activated (Chan and Hemler, 1993).
Finally, the CD31-a vb 3 receptor-ligand pair has important
implications for angiogenesis and endothelial biology since
endothelial cells express both a vb 3 and CD31. Blocking a vb 3
either by mAbs or peptide antagonists has been shown to
inhibit angiogenesis and increase apoptosis (Brooks et al.,
1994). Furthermore, we have previously shown that CD31(D1-
D6) Fc inhibits the growth of endothelial cells and mAbs to
CD31 disrupt endothelial monolayer formation (Fawcett et al.,
1995). Thus, CD31-CD31 homotypic adhesion and CD31-
a vb 3 heterotypic adhesion may provide key signals to regulate
endothelial proliferation and differentiation.
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